Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBT2 extension study in prodromal or mild Alzheimer's disease
ACTRN12613000777796Phase 2Completed
- Sponsor
- Alterity Therapeutics
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PBT2 in Alzheimer's disease (AD), sponsored by Alterity Therapeutics. Primary endpoints: Safety and tolerability of PBT2 and Brain amyloid burden by PiB-PET. Started Jul 2013; status: completed.
02
Drugs
PBT2
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12613000777796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000777796.